Ibrutinib: Targeting the hidden CLL

Research output: Contribution to journalReview articlepeer-review


In this issue of Blood, Herman et al elucidate the in vivo effects of ibrutinib (a BTK inhibitor) in various disease compartments of patients with chronic lymphocytic leukemia (CLL).

Original languageEnglish (US)
Pages (from-to)3215-3216
Number of pages2
Issue number21
StatePublished - May 22 2014
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Ibrutinib: Targeting the hidden CLL'. Together they form a unique fingerprint.

Cite this